By admin 
The esteemed journal Nature Aging, a critical forum for cutting-edge research in gerontology, provides the perfect platform for this comprehensive review, which serves as both a synthesis of existing knowledge and a strategic roadmap for future investigations. The collaborative nature of this work, spanning multiple institutions across Norway, Denmark, Japan, and the United States, exemplifies the interdisciplinary and international cooperation deemed essential to unravel the complex mysteries of aging and its associated pathologies. This global scientific alliance highlights a shared recognition that conquering age-related decline requires diverse perspectives and concerted efforts.
At the heart of this discussion lies NAD+, often colloquially referred to as a cell’s "fuel regulator" due to its indispensable role in myriad cellular processes vital for life. Its functions extend far beyond mere energy production; NAD+ is a critical coenzyme involved in a vast array of metabolic reactions, acting as a pivotal electron carrier in processes like glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation, ultimately leading to the generation of adenosine triphosphate (ATP), the primary energy currency of the cell. Without sufficient NAD+, mitochondrial function falters, leading to energy deficits that can compromise cellular integrity and function.
Beyond its energy-generating capabilities, NAD+ is an essential substrate for several key enzyme families that regulate DNA repair, gene expression, and cellular stress responses. These include sirtuins (SIRT1-7), a family of protein deacetylases and ADP-ribosyltransferases that are crucial for maintaining genomic stability, regulating metabolism, and influencing lifespan. Poly-ADP-ribose polymerases (PARPs), another NAD+-dependent enzyme family, are critical for sensing and repairing DNA damage. When DNA damage occurs, PARPs rapidly consume NAD+ to initiate repair processes, thereby protecting the genome. However, chronic DNA damage, often observed in aging, can lead to excessive PARP activation and a significant depletion of cellular NAD+ pools. CD38, an enzyme involved in calcium signaling, also contributes to NAD+ degradation, and its activity has been shown to increase with age. Thus, NAD+ acts as a linchpin, integrating energy metabolism with genomic maintenance and cellular resilience.
The review meticulously details how NAD+ levels naturally and precipitously decline as individuals age. This age-related decrease is not merely a benign consequence but is intricately linked to a spectrum of physiological declines and increased susceptibility to chronic diseases. The reduction in NAD+ has been robustly associated with hallmark features of aging, including genomic instability, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, altered intercellular communication, stem cell exhaustion, chronic inflammation, and deregulated nutrient sensing. Specifically, the decline has been causally implicated in observed age-related memory problems, a reduction in muscle strength and physical endurance, and a heightened risk for a panoply of age-related diseases, including cardiovascular disease, metabolic syndrome, and, critically, neurodegenerative disorders like Alzheimer’s and Parkinson’s disease, where impaired mitochondrial function and accumulated cellular damage are prominent features.
"The precise modulation of NAD+ metabolism holds immense promise for not only delaying the onset and progression of age-related health decline but also for intervening in premature aging diseases and various chronic conditions," articulated Dr. Jianying Zhang, one of the distinguished lead authors of the review. Dr. Zhang’s statement, however, is tempered with a crucial caveat, reflecting the scientific community’s cautious optimism: "But to truly unlock its full therapeutic potential, we need to achieve a far deeper and more nuanced understanding of the optimal doses, assess long-term safety profiles comprehensively, and unravel the significant interindividual variability in response to NAD+ augmentation strategies." This emphasizes the need for rigorous scientific investigation to move beyond promising preliminary results and establish clinically viable interventions.
The review meticulously synthesizes years of rigorous laboratory research and nascent clinical studies that have explored diverse strategies to elevate NAD+ levels within the body. A primary focus of these approaches involves the administration of vitamin-like compounds, known as NAD+ precursors, most notably nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These compounds are readily absorbed and subsequently converted into NAD+ through specific enzymatic pathways within cells. NR, for instance, is phosphorylated by nicotinamide riboside kinase (NRK) enzymes to NMN, which is then converted to NAD+ by NMN adenylyltransferase (NMNAT) enzymes. NMN directly enters the NAD+ synthesis pathway via NMNATs.
Early findings from both preclinical models and a growing number of human clinical trials have indeed been promising. These studies have reported a range of beneficial outcomes, including improvements in cognitive functions such as memory and processing speed, enhancements in physical movement and muscle performance, and significant positive impacts on various markers of metabolic health, such as insulin sensitivity and lipid profiles. For example, some trials have indicated that NAD+ precursors can improve mitochondrial respiration and reduce inflammatory markers, both of which are critical in the context of healthy aging and disease prevention.
Despite these encouraging initial data, the researchers are resolute in stressing the imperative for larger-scale, longer-duration clinical trials involving diverse patient populations. Such extensive studies are indispensable to unequivocally confirm the efficacy, safety, and durability of these NAD+-boosting interventions across a broad spectrum of diseases and in varied demographic groups. The complexity of human physiology and the multifactorial nature of age-related diseases necessitate robust evidence that extends beyond preliminary findings.
The publication of this comprehensive review arrives at a particularly pertinent juncture, coinciding with an accelerating surge of interest from both the scientific community and the general public in NAD+ and its potential therapeutic applications. Across the globe, numerous clinical trials are actively underway, including several significant studies within Norway, rigorously evaluating the effects of NAD+ precursors like NR and NMN in human subjects. These trials span a wide array of conditions, from metabolic disorders to neurodegenerative diseases, reflecting the broad therapeutic potential attributed to NAD+.
Concurrently, these very compounds have rapidly permeated a burgeoning global supplement market. This commercialization, often preceding definitive clinical evidence, has inevitably led to considerable debate and a degree of confusion regarding the efficacy of various commercial formulations, optimal dosing regimens, and, crucially, whether the compelling results observed in animal models will reliably translate into comparable benefits in human subjects. The gap between preclinical success and clinical translation is a well-documented challenge in medical research, particularly in the complex realm of aging.
"This rapidly evolving landscape, characterized by both scientific breakthroughs and public interest, is precisely why we believe the timing is unequivocally right to share a consolidated expert opinion," stated Dr. Evandro Fei Fang-Stavem, the distinguished senior author of the paper and head of the innovative Fang Lab at UiO and Ahus. Dr. Fang-Stavem elaborated on the current challenges: "NAD+ is fundamental to life itself, yet there is still a pervasive confusion and considerable ‘noise’ within the field concerning which supplements truly work best, how they should be appropriately used, and what constitutes evidence-based practice. Our article serves to consolidate the scattered evidence, clarify misconceptions, and, critically, provide a robust scientific roadmap designed to guide both ongoing research efforts and inform future clinical applications with greater precision and confidence."
Further underscoring the critical need for this review, Professor Torbjørn Omland, MD, PhD, MPH, Deputy Head of the Institute of Clinical Medicine and a distinguished co-author of the paper, emphasized the current knowledge gaps. "There exists a significant knowledge gap on NAD+ and its multifaceted clinical effects, particularly for both basic researchers and practicing clinicians," Prof. Omland noted. "This review paper therefore provides the latest, most authoritative expert opinion to those who are keenly interested in and actively working within the dynamic field of NAD+ research. Crucially, this comprehensive review will also provide highly relevant and actionable information to the multitude of NAD+-based clinical trials currently underway across a wide spectrum of clinical conditions, encompassing critical areas such as neurological and cardiovascular disease, where NAD+ dysregulation is increasingly implicated."
The authors collectively and emphatically stress that while NAD+-based supplements and therapeutic strategies are undergoing widespread investigation, the path forward necessitates an unwavering commitment to stronger international collaboration and, most critically, more rigorous, well-designed, and large-scale clinical testing. These foundational steps are absolutely essential to bridge the gap between promising early findings and the eventual development of safe, effective, and evidence-based treatments for the complex challenges of aging and the myriad age-related diseases that impact global health. This call for enhanced rigor includes the need for standardized methodologies, robust patient stratification, identification of reliable biomarkers to monitor NAD+ status and treatment response, and long-term follow-up studies to ascertain sustained benefits and potential late-onset side effects.
The collaborative spirit of this endeavor is exemplified by the diverse contributions from leading researchers. Norwegian contributors include Sofie Lautrup (UiO and Ahus), Hilde Loge Nilsen (OUS), Leiv Otto Watne (Ahus and UiO), Geir Selbæk (UiO and Norwegian National Centre for Ageing and Health), Mathias Ziegler (UiB), Ole-Bjørn Tysnes (UiB), and Charalampos Tzoulis (UiB). These individuals represent a formidable concentration of expertise in aging biology, neuroscience, and clinical medicine within Norway. Their contributions are complemented by additional distinguished authors affiliated with world-renowned institutions such as the University of Copenhagen (Denmark), Chiba University (Japan), Harvard Medical School (USA), and the Buck Institute for Research on Aging (USA). This formidable international consortium underscores the global significance and universal implications of NAD+ research in the quest for healthier, longer lives. The collective expertise assembled for this review serves as a powerful testament to the collaborative, interdisciplinary approach required to tackle one of humanity’s most profound challenges: the biological process of aging and its devastating consequences.